ABBVIE

The article discusses the importance of enabling JavaScript for optimal app performance.

Alzheimer’s disease therapeutics market includes symptomatic treatments (cholinesterase inhibitors, NMDA receptor antagonists) and disease-modifying therapies (anti-amyloid monoclonal antibodies). Market growth driven by aging population, diagnostic advancements, and R&D investments. Market expected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033 at 18.8% CAGR. Major companies include Biogen, Merck, GSK, Novartis, Johnson & Johnson, Bristol Myers Squibb, Sanofi, Pfizer, Teva Pharmaceutical, and AbbVie, each with strategic initiatives and collaborations in Alzheimer’s research.

AbbVie's ELAHERE® (mirvetuximab soravtansine) receives European Commission approval for treating platinum-resistant ovarian cancer, marking the first FRα-directed ADC in the EU. ELAHERE demonstrated overall survival benefits in a Phase 3 trial, supported by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay for patient selection.

ELAHERE® (mirvetuximab soravtansine) receives European Commission approval for treating FRα-positive, platinum-resistant ovarian cancer, marking the first ADC therapy in the EU to show overall survival benefit in a Phase 3 trial. The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, used to identify eligible patients, also gets CE Mark.

AbbVie's ELAHERE (mirvetuximab soravtansine) approved by the European Commission for FRa-positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received 1-3 prior treatments. ELAHERE is the first FRα-directed ADC medicine approved in the EU, Iceland, Liechtenstein, Norway, and Northern Ireland. FDA approved in the U.S. in March 2024.

ELAHERE, a novel therapy for folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer, receives EU approval. It's the first treatment to show overall survival benefit in a Phase 3 trial vs. chemotherapy. The companion diagnostic, VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, also gets CE Mark.

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first IHC companion diagnostic test in Europe to identify ovarian cancer patients eligible for ELAHERE treatment.

Bristol Myers Squibb's Cobenfy, approved by the FDA in September, marked a significant breakthrough in schizophrenia treatment, while AbbVie's muscarinic candidate emraclidine failed mid-stage trials, positioning BMS as the clear winner. Cobenfy's efficacy in three registrational trials contrasts with emraclidine's failure to show significant symptom improvement in Phase II trials, leading to a 12% drop in AbbVie's stock. BMS's acquisition of Karuna Therapeutics for $14 billion in December 2023 further solidified its lead in the schizophrenia market.

Sarilumab more effective than methotrexate in enabling steroid taper in polymyalgia rheumatica patients, according to ACR Convergence 2024 data.